Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO
LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
IN THE NEOADJUVANT SETTING
Description for laymen
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO
LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
IN THE NEOADJUVANT SETTING
JSON Data
{
"short_title": "FourLight-2",
"data_mode": "900",
"data_mode_number": "000002440",
"official_title": "AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, \r\nPHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO \r\nLETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER \r\nWITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER \r\nIN THE NEOADJUVANT SETTING",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "neoadjuvant",
"therapielinie_value": "first",
"ctgov_number": "NCT06465368",
"eudract_number": "2024-512848-30",
"general_contact_email": "studiensekretariat.gyn@ukdd.de",
"general_contact_phone": "+49 351-4584202",
"hauptpruefer_dd_name": "Dr. Theresa Link",
"description_laie_de": "Eine interventionelle, offene, randomisierte, multizentrische Phase-2-Studie mit PF-07220060 plus Letrozol im Vergleich zu Letrozol allein bei postmenopausalen Frauen ab 18 Jahren mit hormonrezeptorpositivem, HER2-negativem Brustkrebs im neoadjuvanten Setting.",
"description_laie_en": "AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO \r\nLETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER \r\nIN THE NEOADJUVANT SETTING",
"description_expert_de": "Eine interventionelle, offene, randomisierte, multizentrische Phase-2-Studie mit PF-07220060 plus Letrozol im Vergleich zu Letrozol allein bei postmenopausalen Frauen ab 18 Jahren mit hormonrezeptorpositivem, HER2-negativem Brustkrebs im neoadjuvanten Setting.",
"description_expert_en": "AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO \r\nLETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER \r\nIN THE NEOADJUVANT SETTING",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "II",
"main_cat_id": 3,
"sub_cat_id": 16
}
